Drug intelligence / Profile preview

thiotepa + cemiplimab

Development stage: Preclinical
Lead developer: Maia Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Intravesical, Intracavitary, Intrathecal

Overview

This combination involves **thiotepa**, an alkylating agent used in chemotherapy to treat various cancers, and **cemiplimab**, a monoclonal antibody acting as a PD-1 inhibitor used in immunotherapy. Thiotepa works by damaging DNA in cancer cells, preventing them from reproducing. Cemiplimab enhances the body's immune response against cancer cells by blocking the PD-1 protein.

Targets

PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on thiotepa + cemiplimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiotepa + cemiplimab.

Explore the full profile